

STATISTICAL ANALYSIS PLAN
For
An Open-Label Phase 2a Study to Evaluate the Safety and Efficacy
of AVB-S6-500 in Patients with IgA Nephropathy

PROTOCOL NUMBER: AVB500-IGA-001
NCT04042623

Sponsor: Aravive, Inc
3730 Kirby Drive, Ste 1200
Houston, Texas 77098
USA

Document Date: 20 October 2021

Aravive, Inc. certifies that Statistical Analysis Plan was not drafted, since the study was terminated after only one patient was enrolled in the study AVB500-IGA-001. This subject received a single dose of the study drug and did not complete the study. No outcome measures were analyzed and there are no plans to conducted any analyses in the future.